ArticleScience advances2022
Microfluidic particle dam for direct visualization of SARS-CoV-2 antibody levels in COVID-19 vaccinees.
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Lab on an end: Micromanipulation using the acoustohydrodynamic pillar array as an end effector.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Advancing Microfluidic Immunity Testing Systems: New Trends for Microbial Pathogen Detection.Molecules (Basel, Switzerland) · 2024Review
- On-Site Melanoma Diagnosis Utilizing a Swellable Microneedle-Assisted Skin Interstitial Fluid Sampling and a Microfluidic Particle Dam for Visual Quantification of S100A1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Antibodies, repertoires and microdevices in antibody discovery and characterization.Lab on a chip · 2024Review
- Effective colloidal emulsion droplet regulation in flow-focusing glass capillary microfluidic deviceRSC advances · 2024Article
- A Mechanical Assay for the Quantification of Anti-RBD IgG Levels in Finger-Prick Whole Blood.ACS sensors · 2023Article
- Next-generation nanophotonic-enabled biosensors for intelligent diagnosis of SARS-CoV-2 variants.The Science of the total environment · 2023Review
- Development of nucleocapsid-specific monoclonal antibodies for SARS-CoV-2 and their ELISA diagnostics on an automatic microfluidic device.Sensors and actuators. B, Chemical · 2023Article
- Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions.Biomedical microdevices · 2023Review
- Application of microfluidic technologies on COVID-19 diagnosis and drug discovery.Acta pharmaceutica Sinica. B · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various COVID-19 vaccines are currently deployed, but their immunization varies and decays with time. Antibody level is a potent correlate to immune protection, but its quantitation relies on intensive laboratory techniques. Here, we report a decentralized, instrument-free microfluidic device that directly visualizes SARS-CoV-2 antibody levels. Magnetic microparticles (MMPs) and polystyrene microparticles (PMPs) can bind to SARS-CoV-2 antibodies simultaneously. In a microfluidic chip, this binding reduces the incidence of free PMPs escaping from magnetic separation and shortens PMP accumulation length at a particle dam. This visual quantitative result enables use in either sensitive mode [limit of detection (LOD): 13.3 ng/ml; sample-to-answer time: 70 min] or rapid mode (LOD: 57.8 ng/ml; sample-to-answer time: 20 min) and closely agrees with the gold standard enzyme-linked immunosorbent assay. Trials on 91 vaccinees revealed higher antibody levels in mRNA vaccinees than in inactivated vaccinees and their decay in 45 days, demonstrating the need for point-of-care devices to monitor immune protection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.